Online inquiry

IVTScrip™ mRNA-Anti-TLR3 Agonist, HspE7(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8452MR)

This product GTTS-WQ8452MR is a type of mRNA modified with 5-Methyl-CTP & Pseudo-UTP, which ecodes the monoclonal antibody that targets TLR3 Agonist. The antibody can be applied in Cervical dysplasia vaccine research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Mycobacterium tuberculosis variant bovis; Alphapapillomavirus 9
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TLR3 Agonist, HspE7(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ8452MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ4269MR IVTScrip™ mRNA-Anti-LINGO1, BIIB-033(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BIIB-033
GTTS-WQ351MR IVTScrip™ mRNA-Anti-ALB&IL6R, 20A11-9mer-ALB11(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 20A11-9mer-ALB11
GTTS-WQ11338MR IVTScrip™ mRNA-Anti-F, MEDI-524(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MEDI-524
GTTS-WQ9273MR IVTScrip™ mRNA-Anti-CEACAM5, IMMU-130(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IMMU-130
GTTS-WQ2470MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7, AMG 181(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG 181
GTTS-WQ3525MR IVTScrip™ mRNA-Anti-APP, BART(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BART
GTTS-WQ380MR IVTScrip™ mRNA-Anti-TYRP1, 20D7S(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 20D7S
GTTS-WQ13953MR IVTScrip™ mRNA-Anti-PDCD1, REGN-2810(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA REGN-2810
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW